Neurocrine Biosciences Inc (NBIX)
Debt-to-capital ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | 169,500 | 0 | 0 | 169,000 | 377,700 | 335,100 | 330,700 | 326,300 | 322,000 | 317,900 | 425,000 | 419,500 | 414,100 | 408,807 | 403,589 | 398,466 | 393,435 |
Total stockholders’ equity | US$ in thousands | 2,232,000 | 2,002,100 | 1,853,000 | 1,684,500 | 1,707,800 | 1,544,600 | 1,423,400 | 1,391,100 | 1,374,000 | 1,346,000 | 1,279,200 | 1,205,600 | 1,126,200 | 804,300 | 831,200 | 700,300 | 636,900 | 574,500 | 483,700 | 409,300 |
Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.00 | 0.11 | 0.21 | 0.20 | 0.20 | 0.20 | 0.21 | 0.22 | 0.35 | 0.34 | 0.37 | 0.39 | 0.41 | 0.45 | 0.49 |
December 31, 2023 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $2,232,000K)
= 0.00
The debt-to-capital ratio for Neurocrine Biosciences, Inc. has been relatively stable over the past eight quarters, ranging from 0.07 to 0.21. A lower debt-to-capital ratio indicates that the company relies less on debt financing compared to its capital structure.
The decreasing trend from Q1 2022 to Q4 2023 suggests that the company has been gradually reducing its reliance on debt to finance its operations and investments. This can be seen as a positive sign as it indicates improved financial stability and lower financial risk.
It is important to consider that an extremely low debt-to-capital ratio might also indicate underutilization of debt as a cheaper source of financing. Conversely, a high debt-to-capital ratio can indicate high financial risk. Therefore, a moderate level of debt-to-capital ratio is generally considered healthy for a company's financial structure.
Overall, based on the trend observed in the debt-to-capital ratio over the past eight quarters, Neurocrine Biosciences, Inc. seems to be managing its debt levels effectively and maintaining a balanced capital structure.
Peer comparison
Dec 31, 2023